HUA MEDICINE 華領醫藥 (Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） (Stock code 股份代號： 2552) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Non-registered Holder(s)(Note 1), Hua Medicine (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.huamedicine.com and the website of The Stock Exchange of Hong Kong Limited (th ...

（於百慕達註冊成立之有限公司） (Stock code 股份代號： 2552) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Registered Shareholders, HUA MEDICINE 華領醫藥 (Incorporated in Bermuda with limited liability) Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders. 各位登記股東： 華領醫藥（「本公司」） —中期報告2025（「本次公司通訊」）之刊發通知 Hua Medicine (the "Company") – Notice of publication of Interim Report 2025 (the "Current C ...

Financial Performance - Hua Medicine reported a sales increase of 108% for Huadongning®, selling approximately 1,764,000 boxes in the first half of 2025 compared to 846,000 boxes in the same period of 2024[10]. - Revenue for the first half of 2025 reached approximately RMB 217.4 million, reflecting a year-on-year growth of 112% after transitioning to full self-commercialization[10]. - Gross profit for the first half of 2025 was approximately RMB 117.8 million, an increase of about RMB 70.1 million or 147% compared to the same period in 2024[12]. - The gross margin improved to 54.2% in the first half of 2025, up 7.7 percentage points from 46.5% in the same period of 2024[12]. - The company recorded a half-year profit of RMB 1.18 billion for the first time, marking a key milestone towards sustainable profitability[24]. - Basic earnings per share for the period was RMB 1.20, compared to a loss of RMB 0.15 per share in 2024[72]. - The company reported a net profit attributable to shareholders of RMB 1,183,946,000 for the six months ended June 30, 2025, compared to a loss of RMB 142,241,000 for the same period in 2024[99]. Income and Expenses - Other income surged to approximately RMB 1,254.6 million, a 2,178% increase, primarily due to milestone revenue from Bayer amounting to RMB 1,243.5 million[12]. - Sales expenses increased only 5% to RMB 64.2 million, while the sales expense as a percentage of revenue dropped from 59.5% in 2024 to 29.5% in 2025[12]. - R&D expenses decreased from RMB 1,197.8 million for the six months ended June 30, 2024, to RMB 658.2 million for the six months ended June 30, 2025, with clinical trial costs dropping by RMB 67 million[30]. - Administrative expenses decreased from RMB 611 million for the six months ended June 30, 2024, to RMB 531 million for the six months ended June 30, 2025, mainly due to a reduction in labor costs of RMB 41 million[31]. - The company incurred financing costs of RMB 3,968,000, slightly up from RMB 3,880,000 in the previous year[72]. Cash Flow and Assets - Cash balance as of June 30, 2025, was approximately RMB 1,022.8 million, providing a solid foundation for future R&D and commercialization plans[10]. - Cash used in operating activities was RMB 844 million for the six months ended June 30, 2025, compared to RMB 2,267 million for the same period in 2024[35]. - The company reported cash and cash equivalents of RMB 1,022.8 million as of June 30, 2025[34]. - Total assets decreased to RMB 1,420,001,000 from RMB 1,527,292,000 as of December 31, 2024[73]. - Current liabilities decreased significantly to RMB 159,488,000 from RMB 330,271,000, reflecting improved liquidity[73]. Market Expansion and Product Development - The company submitted a registration application for dorzagliatin 75mg in Hong Kong, aiming to expand its business in Greater China and Southeast Asia[10]. - Ongoing post-marketing studies are evaluating the long-term safety and efficacy of dorzagliatin in various patient populations, further supporting its potential as a diabetes treatment[11]. - The company plans to initiate bioequivalence studies for the fixed-dose combination of dorzagliatin and metformin in early 2026, following the completion of pre-IND data submission in August 2025[18]. - The company is exploring partnerships in Southeast Asia and countries along the Belt and Road Initiative to expand the market for dorzagliatin and second-generation GKAs[21]. Employee and Shareholder Information - As of June 30, 2025, the company has a total of 285 employees, with 52% in sales and marketing, 22% in R&D, and 4% in production[56]. - Employee costs for the six months ending June 30, 2025, were approximately RMB 97.0 million, an increase of 19.5% from RMB 81.4 million for the same period in 2024[57]. - The company has adopted two share plans: the pre-IPO share incentive plan and the post-IPO share option plan, with 9,700,000 shares available for issuance under these plans during the reporting period[58]. - The company has established an employee trust to manage the pre-IPO share incentive plan, issuing a total of 117,000,000 shares to the trustee[59]. - The company’s directors hold a total of 74,436,450 unexercised options as of June 30, 2025, which includes 3,410,000 options granted during the period[113]. Corporate Governance and Compliance - The company has adopted the corporate governance code and confirmed compliance with all applicable provisions during the six months ending June 30, 2025[135]. - The company's interim financial performance for the six months ending June 30, 2025, has been reviewed by Deloitte, confirming compliance with applicable accounting principles and sufficient disclosure[139]. - The company has maintained high levels of corporate governance to protect shareholder interests and enhance corporate value[134].

FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 華領醫藥 | | | | | | 呈交日期: | 2025年9月4日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02552 | 說明 | 普通股 | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | --- | --- | --- | --- | --- | --- | --- | | 上月底結存 | | 2,000,000,000 | USD | 0.001 | USD | 2,000,000 | | ...

Core Viewpoint - 华领医药-B (02552) has seen a significant stock price increase of over 14%, reaching a new high of 4.7 HKD since February 2023, driven by strong mid-year performance and successful commercialization efforts [1] Financial Performance - 华领医药 reported a 2025 mid-year performance with sales volume of Huatangning reaching 1.764 million boxes, a year-on-year increase of 108% [1] - Net sales amounted to 217.4 million CNY, reflecting a year-on-year growth of 112% [1] - The company confirmed a one-time deferred income of 1.2435 billion CNY after terminating the exclusive promotion agreement with Bayer, leading to a profit of 1.1839 billion CNY in the first half of the year, marking its first profitable period [1] - Gross margin improved to 54.2%, an increase of 7.7 percentage points year-on-year, indicating a clear positive trend in profitability [1] Business Expansion - The company is actively expanding its overseas business and accelerating its global layout [1] - A registration application for Myhomsistm (multiglitazone 75mg) has been submitted in Hong Kong, which will enhance its presence in the Greater China and Southeast Asia markets [1] - Based on preliminary success from the Phase I single-dose escalation study in the U.S., the company plans to initiate a multi-dose escalation Phase I study by the end of 2025 or early 2026, continuing to drive the development of the second-generation GKA in the global market [1]

Core Viewpoint - 华领医药-B (02552) has shown significant stock performance, rising over 14% and reaching a new high since February 2023, driven by strong mid-year results and successful commercialization efforts [1] Financial Performance - 华领医药 reported a sales volume of 1.764 million boxes for 华堂宁®, representing a year-on-year increase of 108% [1] - The net sales reached 217.4 million yuan, up 112% year-on-year [1] - The company confirmed a one-time deferred income of 1.2435 billion yuan after terminating the exclusive promotion agreement with Bayer, leading to a profit of 1.1839 billion yuan in the first half of the year, marking its first profitable period [1] - Gross margin improved to 54.2%, an increase of 7.7 percentage points year-on-year, indicating a positive trend in profitability [1] Business Expansion - The company is actively expanding its overseas business and accelerating its global layout [1] - A registration application for 多格列艾汀 75mg (华领片®, MYHOMSISTM) has been submitted in Hong Kong, which will enhance its presence in the Greater China and Southeast Asia markets [1] - Based on the preliminary success of the Phase I single-dose escalation study in the U.S., the company plans to initiate a multi-dose escalation Phase I study by the end of 2025 or early 2026, continuing to drive the development of the second-generation GKA in the global market [1]

Group 1: Market Overview - The Hang Seng Index fell by 0.61%, down 157 points, closing at 25,460 points, while the Hang Seng Tech Index dropped by 1.78% [1] - The early trading volume in the Hong Kong stock market reached HKD 183.6 billion [1] Group 2: Banking Sector Performance - Chinese banks showed a significant recovery in performance for the first half of the year, attracting insurance capital inflows amid asset scarcity [1] - Chongqing Rural Commercial Bank rose by 4.15%, Agricultural Bank of China increased by 3.65%, and Postal Savings Bank of China gained 2.50% [1] Group 3: Notable Stock Movements - Haotian International Investment surged over 11% as its subsidiary plans to apply for virtual asset trading services [1] - Yunfeng Financial increased by over 8% following a strategic cooperation agreement with Ant Group and investment in Pharos blockchain [1] - China Nonferrous Mining rose over 4% due to rising copper prices improving mid-term performance [1] - Saint Noble Pharmaceutical-B saw a mid-day increase of over 10%, with a 91% year-on-year reduction in shareholder losses [1] - Hualing Pharmaceutical-B gained 2.67%, achieving its first profit in the first half of the year [1] Group 4: Declining Stocks - Chenming Paper Industry fell over 5% due to ongoing production line maintenance, reporting a loss exceeding CNY 3.8 billion for the first half [2] - ZTE Corporation dropped over 8% as its mid-term gross margin significantly declined, with analysts suggesting market optimism was excessive [2] - JS Global Life fell over 8%, reporting a shareholder loss of USD 5,924.2 million and a decrease in gross margin from third-party sales [3] - New Quality Digital plummeted over 11%, with its stock price halved in three trading days due to forced sale of shares by an executive [4]

Core Viewpoint - 华领医药-B (02552) has shown significant growth in its mid-term performance, indicating a successful commercial transformation and expansion in both domestic and international markets [1] Financial Performance - 华领医药 reported a sales volume of 1.764 million boxes for 华堂宁, representing a year-on-year increase of 108% [1] - The net sales revenue reached 217.4 million yuan, up 112% year-on-year [1] - The company achieved a profit of 1.1839 billion yuan in the first half of the year, marking its first profitable period [1] - Gross margin improved to 54.2%, an increase of 7.7 percentage points compared to the same period last year [1] Operational Highlights - Following the termination of the exclusive promotion agreement with Bayer, the company confirmed a one-time deferred income of 1.2435 billion yuan [1] - The expansion of production scale and improvement in operational efficiency have contributed to the positive profit trend [1] Market Expansion - The company has successfully increased prescription volumes in secondary and tertiary hospitals due to the continuous expansion of medical insurance coverage [1] - 华领医药 is actively pursuing overseas business opportunities to accelerate its global expansion [1] Research and Development - The company continues to invest in research and development to support its expansion into international markets [1]

Core Viewpoint - 华领医药-B (02552) has shown significant growth in its mid-term performance, indicating successful commercialization and operational efficiency improvements [1] Financial Performance - 华堂宁 sales reached 1.764 million boxes, a year-on-year increase of 108% [1] - Net sales amounted to 217.4 million yuan, reflecting a 112% year-on-year growth [1] - The company reported a one-time deferred income of 1.2435 billion yuan following the termination of the exclusive promotion agreement with Bayer [1] - The company achieved a profit of 1.1839 billion yuan in the first half of the year, marking its first profitable period [1] - Gross margin increased to 54.2%, up 7.7 percentage points from the same period last year [1] Operational Highlights - The company has significantly increased its sales through its own sales team since taking over the commercialization of 华堂宁 in January 2025 [1] - There has been a substantial increase in prescription volumes in secondary and tertiary hospitals, aided by the expansion of medical insurance coverage [1] Strategic Initiatives - 华领医药 is actively expanding its overseas business and accelerating its global layout [1] - The company continues to invest in research and development to support its expansion into international markets [1]

Core Viewpoint - The Hong Kong stock market has seen significant growth in the first half of the year, particularly in the innovative drug sector, driven by increased funding and favorable policies supporting drug innovation in China [1] Industry Summary - The Hang Seng Biotechnology Index has surged over 95% this year, reflecting strong investor interest in the innovative drug sector [1] - China's drug innovation capabilities have gained international recognition, with a robust pipeline of innovative drugs from domestic companies [1] - The National Healthcare Security Administration and the National Health Commission have introduced measures to support the high-quality development of innovative drugs, establishing a dual support system of basic medical insurance and commercial insurance [1] Company Summary - Hualing Pharmaceutical (2552.HK), a leading innovative diabetes drug company, reported impressive results for the first half of 2025, with sales of Huadongning® reaching 1.764 million boxes, a 108% year-on-year increase, and net sales of 217.4 million RMB, up 112% [2][3] - The company achieved its first profit since its listing, with a pre-tax profit of 1.1839 billion RMB, following the termination of its exclusive promotion agreement with Bayer [2] - Hualing Pharmaceutical's self-built sales team has significantly reduced sales expenses from 59.5% to 29.5% of revenue, demonstrating the effectiveness of its commercialization strategy [3] - The company is actively engaged in global research collaborations, including a Phase I clinical study in the U.S. for a new diabetes treatment, and has presented its findings at major scientific conferences [4] - Hualing Pharmaceutical is expanding its market presence in Greater China and Southeast Asia, with plans to submit new drug applications and explore partnerships in the region [5] - The company's global strategy includes the development of a second-generation GKA drug, which has shown positive results in clinical trials in the U.S., targeting the overseas diabetes medication market [5][6]